{"links":{"html":"https://www.erudio.com/reports/ea3191-nct04671667","json":"https://www.erudio.com/reports/ea3191-nct04671667.json","markdown":"https://www.erudio.com/reports/ea3191-nct04671667.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"ea3191-04671667"}},"request":"https://www.erudio.com/contact?report=ea3191-04671667"},"offer":{"cited_commentary_sources":9,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":24,"optional":true,"price_per_verified_person_usd":15,"price_usd":360,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"ea3191-nct04671667"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=ea3191-04671667","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/ea3191-nct04671667","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"focused","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-07T21:39:01.340971Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":1,"discussed":9,"no_commentary_found":0},"aspects":[{"claim_count":13,"coverage":"discussed","id":"A1","source_count":4,"title":"Postoperative replacement rationale and comparator status"},{"claim_count":20,"coverage":"discussed","id":"A2","source_count":2,"title":"Resectability, prognosis and preoperative immunotherapy"},{"claim_count":6,"coverage":"discussed","id":"A3","source_count":2,"title":"Response-dependent sequencing and temporary deferral"},{"claim_count":12,"coverage":"discussed","id":"A4","source_count":2,"title":"Symptoms and alternative systemic-trial choices"},{"claim_count":8,"coverage":"discussed","id":"A5","source_count":1,"title":"Brachial plexus dose estimation, interval and neurologic risk"},{"claim_count":14,"coverage":"discussed","id":"A6","source_count":1,"title":"Reirradiation definition, work-up, intent and technique"},{"claim_count":10,"coverage":"discussed","id":"A7","source_count":1,"title":"Recovery assumptions, cumulative-dose calculations and QA"},{"claim_count":6,"coverage":"discussed","id":"A8","source_count":1,"title":"Function, symptoms and multidisciplinary support"},{"claim_count":14,"coverage":"discussed","id":"A9","source_count":5,"title":"Postoperative selection, referral, consent and accrual"},{"claim_count":0,"coverage":"assessment_incomplete","id":"A10","source_count":0,"title":"Observed comparative survival, symptom and safety outcomes"}],"counts":{"cited_sources":9,"claims_by_expression_type":{"comparison":12,"experience":12,"interpretation":9,"opinion":22,"question":17,"restatement":17,"uncertainty":12,"unspecified":15},"claims_by_kind":{"counterview":1,"interpretation":9,"limitation":6,"source_observation":100},"evidence_units":65,"findings":8,"people_cited":13,"people_identity_verified":24,"people_total":29,"screened_sources":9,"verified_claims":116},"depth":"thin","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"A potentially less-toxic replacement is the hope—not an established advantage"},{"id":"F2","title":"Resectability and patient goals separate the curative discussion from systemic treatment and response-dependent deferral"},{"id":"F3","title":"Symptom burden makes control-arm composition consequential in the connected discussion of alternative trials"},{"id":"F4","title":"Brachial plexus protection is described as a cumulative-dose, interval and counseling problem"},{"id":"F5","title":"Reirradiation questions extend from diagnosis and intent to dose, field size and acceptable harm"},{"id":"F6","title":"Cumulative-dose calculations and recovery assumptions are viewed as uncertain and operationally fragile"},{"id":"F7","title":"Multidisciplinary support is part of treatment feasibility, including during palliative systemic therapy"},{"id":"F8","title":"Access, consent and accrual are practical conditions for answering the research question"}],"medical_affairs_question":"How should Medical Affairs explain the rationale for replacing postoperative platinum chemoradiation without implying that pembrolizumab has already improved efficacy or reduced toxicity?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A potentially less-toxic replacement is the hope—not an established advantage"},{"id":"section-2","level":2,"title":"Resectability and patient goals separate the curative discussion from systemic treatment and response-dependent deferral"},{"id":"section-3","level":2,"title":"Symptom burden makes control-arm composition consequential in alternative-trial counseling"},{"id":"section-4","level":2,"title":"Brachial plexus protection is a cumulative-dose, interval and counseling problem"},{"id":"section-5","level":2,"title":"Reirradiation questions extend from diagnosis and intent to acceptable harm"},{"id":"section-6","level":2,"title":"Recovery assumptions and cumulative-dose workflows remain uncertain"},{"id":"section-7","level":2,"title":"Multidisciplinary support is part of treatment feasibility"},{"id":"section-8","level":2,"title":"Access, consent and accrual are conditions for answering the research question"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2"},"identity":{"accepted_at":"2026-10-07T21:39:01.340971Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-06T15:20:49Z","record_hash":"9db9a6198b80f7c940aef70be7e5d5f608b28b71c791dd12f333d0bb2ee498d8","release_hash":"b2013786f75a6b2db43ddfd6228ddc5fad068187a3c2fa93903adaecf4e863ef","report_id":"erudio-nct04671667","run_id":"4783771c-b441-40ec-bd75-0667bccc4d70","schema_version":"5.0","slug":"ea3191-04671667","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"EA3191 frames a clinician question: can pembrolizumab replace chemotherapy with another radiation course after surgery for previously irradiated, high-risk recurrent or second-primary head and neck squamous cell cancer? Clinician discussions also cover the comparator’s role, resectability, preoperative immunotherapy, treatment sequencing, symptoms and systemic-treatment alternatives. Other topics include cumulative-dose estimation, organ recovery, nerve injury risk, treatment goals, supportive care, referral, consent and trial access. The account draws on supplied video, podcast and X-thread commentary.","meta_description":"9 HCP sources screened · 116 verified claims from 9 sources · 8 findings. Updated 2026-10-07.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-53395b456dc161792d81"],"id":"F4","paraphrase":"A speaker in an X thread asked how to reduce brachial plexus injury during repeat radiation when treatment fields overlap.","source_channel":"x_thread","source_date":"2025-08-16","title":"Brachial plexus protection is described as a cumulative-dose, interval and counseling problem"},{"cited_claim_ids":["claim-352fb056fc01a05084fa","claim-d425403cdb499657ff7b-70de3fb1"],"id":"F6","paraphrase":"Speakers in an X thread asked whether recovery estimates should address organs other than the spinal cord and whether quality assurance should be part of reirradiation.","source_channel":"x_thread","source_date":{"reason":"The thread lists 2023-04-25 and 2023-04-27 without mapping these questions to individual post dates.","status":"unmapped"},"title":"Cumulative-dose calculations and recovery assumptions are viewed as uncertain and operationally fragile"}]},"publication":{"approved_at":"2026-10-06T15:20:49Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-07T22:58:00Z","summary":"Trial study IDs and short name taken from the registry record"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":8,"retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:source_uncertainty:mcp:youtube:SfPRPVb3qPU@40768:41945: The available reply begins mid-condition, so the full condition preceding the first-line trial-candidacy statement cannot be recovered. Keep the condition unspecified, as in the replacement claim.","commentary:source_uncertainty:mcp:youtube:SfPRPVb3qPU@40768:41945,mcp:youtube:SfPRPVb3qPU@42013:42205: The source identifies these remarks only as an unidentified speaker; no source-supported name is established for the remarks. Retain the commentary as unnamed and do not infer an identity.","commentary:held_out:mcp:youtube:SfPRPVb3qPU@40768:41945,mcp:youtube:SfPRPVb3qPU@39680:40334,mcp:youtube:SfPRPVb3qPU@40336:40441,mcp:youtube:SfPRPVb3qPU@40506:40703: a claim treats the trial-candidacy condition as unrecoverable, but the supplied preceding video turns recover it. mcp:youtube:SfPRPVb3qPU@40336:40441 says “if it proved not to be resectable,” and mcp:youtube:SfPRPVb3qPU@40506:40703 continues the hypothetical with an operation finding disease against the carotid. The speaker remains unidentified, but the unresectability qualification is available within this source. The report repeatedly turns an excerpt boundary into a missing-context limitation.","commentary:held_out:mcp:youtube:SfPRPVb3qPU@48494:50468: The retained case recap omits Mehra’s additional treatment-selection views: the multidisciplinary difficulty in finding an answer and surgery’s omission from the poll; PD-1 monotherapy being reasonable with low symptom burden despite modest CPS 8, particularly when quality of life and minimizing toxicity are essential; chemotherapy plus PD-1 also being reasonable; the emerging PD-1/cetuximab evidence and platinum-refractory research context; and her view that re-irradiation toxicities would lead many clinicians probably not to use it initially. These are absent from the verified claims and supporting quotations.","commentary:held_out:mcp:youtube:SfPRPVb3qPU@48494:50468,mcp:youtube:SfPRPVb3qPU@50470:51790: The report retains multidisciplinary collaboration but not Mehra’s specific recommendation about when to re-engage the team. She endorses doing so before systemic-treatment decisions and explains that early re-engagement is reasonable because surgery or radiation colleagues who treated the patient previously are likely already known to the patient.","commentary:held_out:mcp:x_thread:1650850190453080065:ad542580-0fc9-4ace-a273-4031fb0d61b9@1381:1596,mcp:x_thread:1650850190453080065:ad542580-0fc9-4ace-a273-4031fb0d61b9@1598:2012: The recovery discussion retains slider use and weak evidence but omits Scher’s request for guidance on determining the percentage forgiven and Ryckman’s conditional proposal for default forgiveness settings. Ryckman gives example percentages and intervals, then explicitly says there is no consensus and questions whether guardrails should be supplied. That qualification is consequential to interpreting recovery-based constraint workflows.","commentary:held_out:mcp:youtube:SfPRPVb3qPU@59235:59760: The connected discussion of chemotherapy plus pembrolizumab omits Mehra’s renal-function-dependent alternative selection. She cites carboplatin/paclitaxel/pembrolizumab from B10, reports that many consider it more feasible than platinum/5-FU/pembrolizumab, and regards carboplatin as reasonable with some baseline kidney dysfunction. This supplies a condition and work-up consideration for an explicitly retained systemic alternative, not postoperative EA3191 dosing guidance.","commentary:held_out:mcp:youtube:SfPRPVb3qPU@59986:60583,mcp:youtube:SfPRPVb3qPU@60664:61371: The alternative-trial synthesis retains response-rate enthusiasm and uncertainty about symptom relief but omits Bhatia’s connected answers about durability and HPV-related evidence limits. She reports duration endpoints for the EGFR/TGF-β agent, says other agents’ data are still maturing, recalls responses in a small HPV-positive EGFR/LGR5-plus-pembrolizumab cohort, and distinguishes those observations from HPV-positive exclusion in two Phase III programs and her suspicion of more limited responses. These are attributed observations and expectations, not EA3191 results or proof that HPV determines response duration.","commentary:held_out:mcp:youtube:SfPRPVb3qPU@53151:53694: The report retains uncertainty about incorporating bispecifics but omits Mehra’s condition for mechanism-based selection among them: robust biomarker development is needed as current trials evolve before target differences can inform which patients should receive which agent. This is a distinct open question relevant to the alternative-treatment choices already synthesized."],"source_count":9,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.","8 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","The reviewed discussion is not representative of all HCP views. Searches centered on identifiers and aliases may have missed unnamed references or different transcription variants.","Related panel recordings and repeated organizational posts are not independent endorsements and should not be used to estimate consensus.","The unidentified video respondent cannot be named from the supplied source. A named podcast passage does not establish ownership of the video remarks.","Some connected discussion is not fully represented: treatment-selection rationale in the case recap, timing of multidisciplinary re-engagement, dose-recovery guidance and its qualifications, renal-function-dependent systemic alternatives, alternative-agent durability and HPV-related evidence limits, and biomarker-based selection among bispecifics. These omissions limit the completeness of the reported decision rationales.","No exact-trial publication, comparative readout or full protocol document was available. Reported regimen, eligibility and dose-limit details remain attached to the speakers who described them.","Post and publication dates are not confirmed session dates. Local availability, enrollment and renovation accounts describe their presentation setting, not assured current access.","Broader reirradiation opinions include other treatment intents and disease sites; they do not establish EA3191-specific dose, target-volume or technique recommendations.","Some presenters have limited separate professional context. Their source-established identities do not justify assuming additional clinical credentials or giving their claims greater evidentiary weight.","The patient-facing video's rendered clinicaltrials.gov link contains NCT05533558 rather than the target NCT04671667; it is retained as transcribed, not endorsed as a verified referral link."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":9},"count":9,"evidence_window":{"end":"2026-10-01","start":"2023-04-25"},"retrieval_snapshot":"2026-10-07T20:54:31.205914Z","timeline":[{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W38"},{"count":1,"week":"2023-W44"},{"count":1,"week":"2025-W33"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT04671667:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04671667:context","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5ddaa0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1650850190453080065:ad542580-0fc9-4ace-a273-4031fb0d61b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1956772008504754423:95cb31ee-d582-45e6-8bb4-3df0fb0b62c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098049215490331056:47fe8b3a-4f85-45a1-9297-3b5c513c3210","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103122450326151267:d687f455-1272-4675-93cb-f6adddfe3172","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105659110704164880:5776b8e7-fc2c-4d9d-97b4-e62bfdf5945a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JWoSDt_rkVI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QON71lKGr9s","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SfPRPVb3qPU","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":9},"count":9,"evidence_window":{"end":"2026-10-01","start":"2023-04-25"},"retrieval_snapshot":"2026-10-07T20:54:31.205914Z","timeline":[{"count":1,"week":"2023-W17"},{"count":1,"week":"2023-W38"},{"count":1,"week":"2023-W44"},{"count":1,"week":"2025-W33"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Head and neck squamous cell carcinoma","slug":"head-and-neck-squamous-cell-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features"],"brief_title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma"],"enrollment":{"count":188,"type":"ESTIMATED"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"Carboplatin","synonyms":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","JM8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Cisplatin","synonyms":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Computed Tomography","synonyms":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Intensity-Modulated Radiation Therapy","synonyms":["IMRT","Intensity modulated radiation therapy (procedure)","Intensity Modulated RT","Intensity-Modulated Radiotherapy","Radiation, Intensity-Modulated Radiotherapy"],"type":"RADIATION"},{"name":"Magnetic Resonance Imaging","synonyms":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Pembrolizumab","synonyms":["BCD-201","GME 751","GME751","Keytruda","Lambrolizumab","MK 3475","MK-3475","MK3475","Pembrolizumab Biosimilar BCD-201","Pembrolizumab Biosimilar GME751","Pembrolizumab Biosimilar QL2107","Pembrolizumab Biosimilar RPH-075","Pembrolizumab Biosimilar SB27","QL2107","RPH 075","RPH-075","RPH075","SB 27","SB-27","SB27","SCH 900475","SCH-900475","SCH900475"],"type":"BIOLOGICAL"},{"name":"Proton Beam Radiation Therapy","synonyms":["External beam radiation therapy protons (procedure)","External Beam Radiotherapy (protons)","PBRT","Proton","Proton EBRT","Proton External Beam Radiotherapy","Proton Radiation Therapy","PROTON Therapy","Radiation, Proton Beam"],"type":"RADIATION"}],"nct_id":"NCT04671667","official_title":"A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"Kaplan-Meier estimates will be used to estimate the OS distributions. A log-rank test with one-sided 10% type I error will be used for the comparison.","measure":"Overall survival (OS)","timeFrame":"From randomization to date of death from any cause, measured at 2 years"},{"description":"Assessed using Common Terminology Criteria for Adverse Events. An 80% confidence interval around the hazard ratio of the two experimental arms will be calculated. Toxicity will be compared between the two treatment arms. Toxicity will be examined by arm and compared using the Fisher's exact test.","measure":"Incidence of adverse events","timeFrame":"Up to 5 years from date of registration"}],"registry_last_updated":"2026-09-22","registry_url":"https://clinicaltrials.gov/study/NCT04671667","short_name":"EA3191","short_name_basis":"sponsor_study_id","sponsor":"National Cancer Institute (NCI)","start_date":{"date":"2021-04-27","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"NCI-2020-13174","type":"sponsor_study_id"},{"domain":"ECOG-ACRIN Cancer Research Group","id":"EA3191","type":"other"},{"domain":"CTEP","id":"EA3191","type":"other"},{"id":"U10CA180820","type":"nih"}],"study_type":"INTERVENTIONAL"}}}